We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
127 hedge funds and large institutions have $49.7M invested in Lineage Cell Therapeutics in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
13,200% more call options, than puts
Call options by funds: $133K | Put options by funds: $1K
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
13% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 16
1% more funds holding
Funds holding: 126 → 127 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.72% less ownership
Funds ownership: 48.6% → 47.89% (-0.72%)
8% less capital invested
Capital invested by funds: $53.8M → $49.7M (-$4.15M)
Holders
127
Holders Change
+1
Holders Change %
+0.79%
% of All Funds
1.7%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
37
Reduced
22
Closed
16
Calls
$133K
Puts
$1K
Net Calls
+$132K
Net Calls Change
+$95K
Top Buyers
| 1 |
BC
Broadwood Capital
New York
|
+$4.63M |
| 2 |
Comerica Bank
Dallas,
Texas
|
+$1.29M |
| 3 |
BlackRock
New York
|
+$797K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$466K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$310K |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$3.64M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.98M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$519K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$348K |
| 5 |
JP Morgan Chase
New York
|
-$200K |
